Cure8 news brief
Longer-term data help patients and clinicians understand whether an initial response to a new biologic (mirikizumab) is likely to last and whether safety findings remain acceptable over two years.
Durability and safety in both biologic-naive patients and those with prior biologic failure are relevant when considering treatment options.
Patients with Crohn’s disease considering or receiving mirikizumab, clinicians who treat IBD, and IBD researchers tracking long-term biologic outcomes.
Among patients who had endoscopic response at week 52, the majority maintained response through week 104; a substantial proportion also maintained or achieved endoscopic and clinical remission by week 104.
Safety findings reported included low percentages of severe treatment-emergent adverse events, serious adverse events, and very few discontinuations due to adverse events.
The report is based on an open-label extension presented at a conference; it describes outcome definitions (SES-CD thresholds and CDAI <150) and uses a modified nonresponder imputation for some analyses. The article cites a presentation (Barnes et al.) and includes author disclosures.
These are results from an open-label extension (VIVID-2) following a phase 3 randomized study; open-label designs and imputation methods can affect interpretation. The article summarizes a conference presentation—read the full study report or peer-reviewed publication for complete methods, detailed safety data, and subgroup analyses.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
These are multi‑year clinical results for a newly approved IL‑23p19 inhibitor (mirikizumab) showing sustained clinical and endoscopic benefit for many patients with moderate‑to‑severe Crohn’s disease, including some who...
The article summarizes recent drug approvals and Phase 3 trial results that could affect which biologic treatments are available and how the Crohn's disease treatment market may change. It also gives epidemiology and...
This press release reports multi-year data suggesting many patients treated continuously with mirikizumab maintained clinical remission and endoscopic response at two years—outcomes people with Crohn’s disease often care...
